Walker, Janek S.
Hing, Zachary A.
Harrington, Bonnie
Baumhardt, Jordan
Ozer, Hatice Gulcin
Lehman, Amy
Giacopelli, Brian
Beaver, Larry
Williams, Katie
Skinner, Jordan N.
Cempre, Casey B.
Sun, Qingxiang
Shacham, Sharon
Stromberg, Benjamin R.
Summers, Matthew K.
Abruzzo, Lynne V.
Rassenti, Laura
Kipps, Thomas J.
Parikh, Sameer
Kay, Neil E.
Rogers, Kerry A.
Woyach, Jennifer A.
Coppola, Vincenzo
Chook, Yuh Min
Oakes, Christopher
Byrd, John C.
Lapalombella, Rosa
Funding for this research was provided by:
National Institutes of Health (NIGMS T32 GM068412, 5P30 CA016058, 5R01 CA223165, R35 CA197734, P30 CA016058)
National Cancer Institute (P01 5P01CA081534, R01 CA182905-01, R35 CA198183)
Cancer Prevention and Research Institute of Texas (RP180410, RP170170)
Article History
Received: 16 August 2020
Accepted: 1 January 2021
First Online: 15 January 2021
Ethics approval and consent to participate
: The authors are grateful to the patients who generously provided blood for the above-mentioned studies. All CLL patient data was obtained after patients provided informed consent and approved by the institutional review board (IRB) from each respective institution. Blood from newly diagnosed untreated CLL patients were obtained from the Ohio State University Leukemia Tissue Bank after obtaining informed consent approved by the cancer institution review board. All mouse protocols were reviewed and approved by The Ohio State University Institutional Animal Care and Use Committee (IACUC).
: Not applicable.
: SS is employed by and is a stockholder of Karyopharm Therapeutics Inc. SS holds Patents (8999996, 9079865, 9714226, PCT/US12/048319, and I574957) on hydrazide containing nuclear transport modulators and uses, and pending Patents (PCT/US12/048319, 499/2012, PI20102724, and 2012000928) on hydrazide-containing nuclear transport modulators and uses. All other authors declare no competing interests.